Can Dazit be used to treat hand‑foot‑mouth disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dazit Should NOT Be Used to Treat Hand-Foot-Mouth Disease

Dazit (maropitant citrate) is a veterinary antiemetic medication approved exclusively for preventing vomiting in dogs and is explicitly labeled "Not for use in humans" - it has no role whatsoever in treating hand-foot-mouth disease (HFMD). 1

Critical Safety Warning

The FDA drug label for Dazit clearly states:

  • "Not for use in humans"
  • "Keep out of the reach of children"
  • The medication can cause localized allergic skin reactions, skin sensitization, and ocular irritation in humans who handle it 1

This is a veterinary medication designed to prevent acute vomiting in dogs, with dosing protocols specific to canine body weight and age 1. There is absolutely no evidence, rationale, or safety data supporting its use in humans for any condition, let alone HFMD.

Appropriate Management of Hand-Foot-Mouth Disease

Since HFMD is a viral illness caused by enteroviruses (primarily coxsackievirus A16 and enterovirus A71), the evidence-based approach is:

Standard Care

  • Treatment is primarily symptomatic and supportive 2
  • The disease is typically self-limiting, resolving in 7-10 days without sequelae 2
  • Focus on pain management for oral ulcers and maintaining hydration 3

Severe/Complicated Cases

  • Intravenous immunoglobulin (IVIG) should be considered for severe cases with complications such as myocarditis, pneumonia, meningitis, or encephalitis 2
  • However, retrospective data suggests no significant advantage of IVIG in mild cases 4

Emerging Treatment Options

Recent research has identified potential therapeutic agents:

  • EPs® 7630 (herbal medicine) showed significant benefit in a 2024 randomized trial, reducing disease duration from 8.58 to 6.07 days and lowering hospitalization rates 5
  • Valacyclovir showed dramatic improvement in a 2026 case report, though this requires further validation 6
  • Traditional Chinese herbs like Jinzhen oral liquid demonstrated reduced symptom duration in controlled trials 7

Diagnostic Confirmation

When diagnosis is uncertain or severe disease is suspected, RT-PCR targeting the 5' noncoding region should be used for enterovirus detection, with VP1 gene sequencing for typing 8

Common Pitfall to Avoid

Do not confuse veterinary medications with human therapeutics. The fact that a medication exists and treats a symptom (like vomiting, which can occur in HFMD) does not make it appropriate for human use, especially when it carries explicit warnings against human administration.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.